AltMountain

Sabby Management, LLC

Location not listed · CRD 162659
Hedge fund managerExempt reporting

Sabby Management, LLC is an exempt reporting adviser that reports managing 1 hedge fund on Form ADV. Its private funds, of all types, hold $52.8 million in gross assets. Over a longer period they returned an estimated +7.0% from Q2 2026 to Q2 2026, compared with +14.8% for the S&P 500, based on 13F filings.

Regulatory assets under management
—Form ADV Item 5.F
Gross assets of private funds
$52.8 millionAll private fund types, Form ADV
Hedge funds managed
12 private funds in total
Employees
—Form ADV Item 5.A
Registration
Exempt reporting adviserCRD 162659
Latest Form ADV
07/08/2026Disciplinary disclosures: none reported

Estimated 13F portfolio performance

Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.

Estimated from 13F · 1 quarters+7.0%Q2 2026 – Q2 2026
S&P 500+14.8%Same quarters, price only
13F holdings$12.0 million16 positions, 2026-06-30
$100$107$115Q2 202613F est. $107S&P 500 $115
QuarterEst. 13F returnS&P 500
Q2 2026+7.0%+14.8%

Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures

Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.

13F holdings as of Sep 30, 2026

All 14 share positions ($6,690,050) reported by Sabby Management, LLC on Form 13F for the quarter ended Sep 30, 2026, filed Nov 13, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.

Share of the reported 13F portfolio, ten largest positions

  • Toyo Co LTD31.35%
  • PN Smart Energy LTD11.02%
  • YXT Com Group Hldg LTD9.66%
  • Zevra Therapeutics Inc9.49%
  • Cervomed Inc8.86%
  • Aptevo Therapeutics Inc6.33%
  • Ishares TR4.15%
  • Paranovus Entertnmnt Tech LT3.90%
  • Senestech Inc3.17%
  • China Pharma Hldgs Inc3.03%
StockValue% of 13F portfolioSharesShares vs prior quarter
Toyo Co LTD$2,097,46131.35%482,175-4.30%
PN Smart Energy LTD$737,06011.02%269,000New
YXT Com Group Hldg LTD$646,5529.66%286,085New
Zevra Therapeutics Inc$634,6159.49%57,850New
Cervomed Inc$593,0448.86%199,678-19.77%
Aptevo Therapeutics Inc$423,4996.33%232,692New
Ishares TR$277,8904.15%1,000New
Paranovus Entertnmnt Tech LT$260,6243.90%64,671-14.27%
Senestech Inc$211,8963.17%313,132+10.45%
China Pharma Hldgs Inc$202,5933.03%308,360New
Can Fite Biofarma LTD$187,4552.80%85,207New
Briacell Therapeutics Corp$158,1832.36%136,365-28.37%
Sidus Space Inc$155,4882.32%85,905+98.04%
Revelation Biosciences Inc$103,6901.55%126,915-39.73%

Changes since Jun 30, 2026

Comparing the share counts in the two quarter-end filings: 7 new positions, 9 sold out, 2 increased, 5 reduced and 0 unchanged.

Number of positions (a count, not dollars)

  • New positions7
  • Increased2
  • Unchanged0
  • Reduced5
  • Sold out9

New positions

StockValueShares
PN Smart Energy LTD$737,060269,000
YXT Com Group Hldg LTD$646,552286,085
Zevra Therapeutics Inc$634,61557,850
Aptevo Therapeutics Inc$423,499232,692
Ishares TR$277,8901,000
China Pharma Hldgs Inc$202,593308,360
Can Fite Biofarma LTD$187,45585,207

Sold out

StockValue at Jun 30, 2026Shares held then
State STR SPDR S&P 500 ETF T$4,107,2355,500
Farmmi Inc$840,3073,515,929
Tempest Therapeutics Inc$567,527511,286
Bioaffinity Technologies Inc$296,905365,647
Smart Powerr Corp$263,214127,774
Briacell Therapeutics Corp$261,53680,721
Inmed Pharmaceuticals Inc$69,70444,970
Nuwellis Inc$49,93516,372
Briacell Therapeutics Corp$11,464120,802

Largest increases

StockChange in sharesChangeValue nowShares now
Sidus Space Inc+42,528+98.04%$155,48885,905
Senestech Inc+29,620+10.45%$211,896313,132

Largest reductions

StockChange in sharesChangeValue nowShares now
Cervomed Inc-49,202-19.77%$593,044199,678
Toyo Co LTD-21,671-4.30%$2,097,461482,175
Revelation Biosciences Inc-83,667-39.73%$103,690126,915
Briacell Therapeutics Corp-54,018-28.37%$158,183136,365
Paranovus Entertnmnt Tech LT-10,769-14.27%$260,62464,671

Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.

From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures

Large ownership stakes (Schedule 13D and 13G)

CompanyFilingPercent of classSharesFiledSource
Oragenics Inc13G9.9%412,654Jan 21, 2026SEC.gov ↗
Tempest Therapeutics, Inc.13G9.9%492,223Jan 21, 2026SEC.gov ↗
Jiuzi Holdings, Inc.13G amendment9.9%206,273Jan 21, 2026SEC.gov ↗
Globavend Holdings Ltd13G9.9%211,464Jan 21, 2026SEC.gov ↗
Foxo Technologies Inc.13G9.9%249,316,528Jan 21, 2026SEC.gov ↗
Revelation Biosciences, Inc.13G9.6%605,702Jan 20, 2026SEC.gov ↗
Nuwellis, Inc.13G5.4%89,685Jan 20, 2026SEC.gov ↗
Lyra Therapeutics, Inc.13G9.9%175,158Jan 20, 2026SEC.gov ↗
InMed Pharmaceuticals Inc.13G9.9%280,138Jan 20, 2026SEC.gov ↗
Biodexa Pharmaceuticals Plc13G9.9%217,600Jan 20, 2026SEC.gov ↗
Big Tree Cloud Holdings Ltd13G6.6%5,769,988Jan 20, 2026SEC.gov ↗
Universe Pharmaceuticals INC13G amendment4.9%28,111Jan 7, 2026SEC.gov ↗
Empery Digital Inc.13G amendment1.3%479,428Jan 7, 2026SEC.gov ↗
BNB Plus Corp.13G amendment4.9%217,840Jan 7, 2026SEC.gov ↗
Transcode Therapeutics, Inc.13G amendment4.9%41,601Jan 7, 2026SEC.gov ↗

A firm files Schedule 13G (passive) or 13D (it may seek to influence the company) when it beneficially owns more than 5% of a class of a public company's shares. Each row is the firm's latest such filing for that company since Jan 7, 2026, exactly as filed, and counts shares held across the firm and its affiliates, not by any single fund. An amendment can report a stake that has fallen below 5%. Holdings may have changed since the filing date. Not verified by AltMountain. Showing the 15 most recent of 16 companies. Source: U.S. Securities and Exchange Commission, EDGAR.

Private funds reported on Form ADV (2)

As reported in the adviser's Form ADV filed Mar 27, 2024. Funds also listed from Form D are shown above.

From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures⁠​​‌‌‌‌‌‌‌‌​​​​​​​​​‌⁠